Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation
RAS效应器MEK 1/2对表皮分化的生理功能
基本信息
- 批准号:8131855
- 负责人:
- 金额:$ 11.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-10 至 2012-08-31
- 项目状态:已结题
- 来源:
- 关键词:Automobile DrivingComplementCoupledDataDevelopmentDifferentiation and GrowthDiseaseDominant-Negative MutationEmbryoEpidermisEpithelialFundingFutureGenesGeneticGoalsGuanosine Triphosphate PhosphohydrolasesHomeostasisHumanIndiumIntegrinsJNK-activating protein kinaseKnockout MiceMAP Kinase GeneMAP Kinase ModulesMAP2K1 geneMAPK8 geneMAPK9 geneMEK inhibitionMEKKsMEKsMaintenanceMalignant - descriptorMalignant NeoplasmsMediatingModelingMusNeoplasmsOncogenicPathway interactionsPhenotypePhysiologicalPlayProtein IsoformsProteinsRNA InterferenceRas/RafRegulationRelative (related person)Research PersonnelResistanceRoleSignal PathwaySignal TransductionSignaling ProteinSkinSquamous cell carcinomaStimulusTherapeuticTherapeutic InterventionTissuesbasehuman tissueinhibitor/antagonistkeratinocyteprogramsresponsetumortumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Physiologic signaling through the Ras/Raf/MEK/ERK and parallel MEKK/JNKK2/JNK MAP kinase cascades regulates normal epidermal homeostasis, while aberrant activation of these pathways drives epidermal neoplasia. MEK and JNK are activated in a majority of spontaneous human epidermal squamous cell carcinomas, however, two isoforms of each protein are expressed in keratinocytes, and clear functional roles for these pathway elements in human epidermis have not been established. MEK1 null mice are embryonic lethal, precluding establishment of epidermal phenotypes; however, MEK2 null mice are normal. This suggests that MEK1 is either functionally dominant, or functionally redundant with MEK2. The epidermal Ras effects of increased proliferation and decreased differentiation are recapitulated only by MEK1, suggesting a primary role for MEK1. However, MEK1/2 share high homology, and the extent to which MEK2 can compensate for MEK1 loss is unknown. To clarify the relative functional roles of MEK1/2 in human epidermal homeostasis, as well as in epidermal tumorigenesis, we will use complementary RNAi and pharmacologic approaches to inhibit MEK1 and MEK2 in human epidermis. The necessity and sufficiency of MEK1/2 to support Ras driven human epidermal tumorigenesis will then be defined. JNK1 and JNK2 appear to have opposing effects in epidermis. Murine epidermis null for JNK1 is hypoplastic, while JNK2 null epidermis is hyperproliferative. However, the thin hypoplastic JNK1 null tissue is more susceptible than wild type skin to tumor formation, while the hyperproliferative JNK2 null tissue is resistant to tumorigenesis. JNK1/2 roles in normal human epidermis will be defined through RNAi, dominant negative and pharmacologic inhibition. The necessity and sufficiency of JNK1/2 to cooperate with Ras in driving human epidermal tumor formation will then be determined. Aims I and II are based on the hypothesis that MEK1/2 and JNK1/2 are required to support key components of Ras driven epidermal tumorigenesis. At the completion on the proposed funding period, we hope to have defined the importance of MEK1/2 and JNK1/2 signaling in both normal human epidermal homeostasis, and in Ras-driven tumorigenesis as a basis for future therapeutic efforts for human disorders of epidermal growth and differentiation, including cancer.
描述(申请人提供):通过Ras/Raf/MEK/ERK和平行的Mekk/JNKK2/JNK MAP激酶级联的生理信号调节正常的表皮稳态,而这些通路的异常激活推动表皮肿瘤的发生。MEK和JNK在大多数自发性人表皮鳞状细胞癌中被激活,但每种蛋白的两种亚型在角质形成细胞中表达,这些通路元件在人表皮中的明确功能尚未确定。MEK1基因缺失的小鼠是胚胎致死的,排除了表皮表型的建立;然而,MEK2基因缺失的小鼠是正常的。这表明MEK1与MEK2要么在功能上占优势,要么在功能上冗余。促进增殖和减少分化的表皮RAS效应仅被MEK1概括,提示MEK1起主要作用。然而,MEK1/2有很高的同源性,并且MEK2可以在多大程度上补偿MEK1的丢失尚不清楚。为了阐明MEK1/2在人类表皮动态平衡以及表皮肿瘤发生中的相关功能,我们将使用互补的RNAi和药理学方法来抑制人类表皮中的MEK1和MEK2。然后将确定MEK1/2支持RAS驱动的人类表皮肿瘤发生的必要性和充分性。JNK1和JNK2在表皮中似乎具有相反的作用。JNK1缺失的小鼠表皮为发育不良,而JNK2缺失的表皮为过度增殖。然而,较薄的发育不良的JNK1缺失组织比野生型皮肤更容易形成肿瘤,而过度增殖的JNK2缺失组织则对肿瘤的形成具有抵抗力。JNK1/2在正常人表皮中的作用将通过RNAi、显性负性和药物抑制来确定。然后将确定JNK1/2与RAS协同作用在促进人表皮肿瘤形成中的必要性和充分性。AIMS I和II的基础假设是MEK1/2和JNK1/2在RAS驱动的表皮肿瘤发生中需要支持关键成分。在拟议的资助期结束时,我们希望明确MEK1/2和JNK1/2信号在正常人类表皮稳态和RAS驱动的肿瘤发生中的重要性,作为未来治疗包括癌症在内的人类表皮生长和分化疾病的基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TODD W RIDKY其他文献
TODD W RIDKY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TODD W RIDKY', 18)}}的其他基金
Impact of Endogenous DOPA Signaling on Melanocyte Homeostasis and Melanoma Susceptibility
内源性多巴信号对黑色素细胞稳态和黑色素瘤易感性的影响
- 批准号:
10475365 - 财政年份:2021
- 资助金额:
$ 11.95万 - 项目类别:
Using Nonclassical Estrogen Signaling to Prevent Melanoma
使用非经典雌激素信号传导预防黑色素瘤
- 批准号:
10112838 - 财政年份:2019
- 资助金额:
$ 11.95万 - 项目类别:
Using Nonclassical Estrogen Signaling to Prevent Melanoma
使用非经典雌激素信号传导预防黑色素瘤
- 批准号:
10580032 - 财政年份:2019
- 资助金额:
$ 11.95万 - 项目类别:
Using Nonclassical Estrogen Signaling to Prevent Melanoma
使用非经典雌激素信号传导预防黑色素瘤
- 批准号:
10381619 - 财政年份:2019
- 资助金额:
$ 11.95万 - 项目类别:
Using Nonclassical Estrogen Signaling to Prevent Melanoma
使用非经典雌激素信号传导预防黑色素瘤
- 批准号:
9895651 - 财政年份:2019
- 资助金额:
$ 11.95万 - 项目类别:
Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation
RAS效应器MEK 1/2对表皮分化的生理功能
- 批准号:
7495164 - 财政年份:2007
- 资助金额:
$ 11.95万 - 项目类别:
Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation
RAS效应器MEK 1/2对表皮分化的生理功能
- 批准号:
7664424 - 财政年份:2007
- 资助金额:
$ 11.95万 - 项目类别:
相似国自然基金
Complement C6蛋白抑制DNA损伤修复增敏甲状腺乳头状癌放射性碘治疗的作用及其机制
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Investigating the role of complement component 5a in ANCA-associated vasculitis
研究补体成分 5a 在 ANCA 相关血管炎中的作用
- 批准号:
MR/Y000854/1 - 财政年份:2024
- 资助金额:
$ 11.95万 - 项目类别:
Fellowship
Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
- 批准号:
10751872 - 财政年份:2024
- 资助金额:
$ 11.95万 - 项目类别:
NSF Convergence Accelerator, Track M: TANDEM: Tensegrity-based Assistive aND rehabilitation Exosuits to complement human bioMechanics
NSF 融合加速器,轨道 M:TANDEM:基于张拉整体的辅助和康复外装,以补充人体生物力学
- 批准号:
2344385 - 财政年份:2024
- 资助金额:
$ 11.95万 - 项目类别:
Standard Grant
Development of a novel oral vaccine for fish: Synergy of chitosan nano particle and complement-mediated opsonization
新型鱼类口服疫苗的开发:壳聚糖纳米颗粒与补体介导的调理作用的协同作用
- 批准号:
24K17960 - 财政年份:2024
- 资助金额:
$ 11.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Crosstalk between purinergic signaling and the complement system in sepsis-induced immunosuppression.
脓毒症引起的免疫抑制中嘌呤能信号传导与补体系统之间的串扰。
- 批准号:
23H03013 - 财政年份:2023
- 资助金额:
$ 11.95万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Complement Protein C1q Regulation of Macrophage Metabolic Pathways
补体蛋白 C1q 对巨噬细胞代谢途径的调节
- 批准号:
10629550 - 财政年份:2023
- 资助金额:
$ 11.95万 - 项目类别:
Complement Resistance Acquired During Acute to Persistent Rubulavirus Infection
急性至持续性风疹病毒感染期间获得的补体耐药性
- 批准号:
10645486 - 财政年份:2023
- 资助金额:
$ 11.95万 - 项目类别:
Defining the impact of complement inhibition by tick saliva in tick-borne virus evolution and adaptive immune responses in murine models of infection
定义蜱唾液抑制补体对蜱传病毒进化和小鼠感染模型适应性免疫反应的影响
- 批准号:
10535945 - 财政年份:2023
- 资助金额:
$ 11.95万 - 项目类别:
Inhibition of Complement Pathways with VCP As A Treatment For Alzheimer's Disease
VCP 抑制补体途径治疗阿尔茨海默病
- 批准号:
10602757 - 财政年份:2023
- 资助金额:
$ 11.95万 - 项目类别:














{{item.name}}会员




